Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE study of aspirin to reduce Tecfidera-associated flushing in relapsing-remitting multiple sclerosis
2013-001895-40Phase 4Completed
- Sponsor
- Biogen
- Start
- Mar 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dimethyl fumarate and aspirin in multiple sclerosis (MS) (3 arms), sponsored by Biogen. Primary endpoint: Incidence and/or severity of flushing events. Started Mar 2014; status: completed.
02
Drugs
dimethyl fumarateaspirin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-001895-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001895-40.